UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported):
May 17, 2005
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
Michigan
(State or other jurisdiction of
incorporation) | | 0-22025
(Commission File No.) | | 94-3096597
(I.R.S. Employer Identification
No.) |
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 48106
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(734) 930-5555
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events.
(b) On May 17, 2005, Aastrom Biosciences, Inc. published a report providing the results from its feasibility clinical trial in Barcelona, Spain to evaluate the use of Tissue Repair Cells (TRCs) for the treatment of severe long bone non-union fractures. This report, which provides the details of the clinical study, including information on each patient treatment and the results obtained, is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
| | | | | |
| Exhibit No. | | Description | | |
| 99.1 | | Report on Barcelona feasibility clinical trial | | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 17, 2005
| | | | | |
| | | AASTROM BIOSCIENCES, INC. |
| | | | | |
| | By: | | /s/ Alan M. Wright |
| | | | |
| | | | Alan M. Wright |
| | | | Senior Vice President, Administrative and |
| | | | Financial Operations, CFO |
3
